Regulatory Information
BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.
BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.
Therapeutic
Prescription Only
Formulation Information
TABLET, FILM COATED
**Dosage and Administration** **Adults** The recommended dose is 5 mg once daily. TRAJENTA can be taken with or without a meal at any time of the day. **Renal impairment** No dose adjustment is required for patients with renal impairment. **Hepatic Impairment** No dose adjustment is required for patients with hepatic impairment. **Elderly** No dose adjustment is necessary. Experience in patients older than > 75 years of age is limited. **Children and adolescents** TRAJENTA is not recommended for use in children below 18 years due to lack of data on safety and efficacy. **_Missed dose_** If a dose is missed, it should be taken as soon as the patient remembers. A double dose should not be taken at the same day.
ORAL
Medical Information
**Indications** TRAJENTA is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. (see Clinical Studies – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_)
**Contraindications** Hypersensitivity to the active ingredient or any of the excipients.
A10BH05
linagliptin
Manufacturer Information
BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.
West-Ward Columbus Inc.
Dragenopharm Apotheker Püschl GmbH
Active Ingredients
Documents
Package Inserts
Package Insert.pdf
Approved: November 16, 2022